Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Bruzzi

Showing results (1-10 of 155) with videos related to

Pageof 16
Sort By:
Annals of the New York Academy of Sciences|July 4, 2002
Objective response to treatment as a potential surrogate marker of survival in breast cancerPaolo Bruzzi
Recenti Progressi in Medicina|July 1, 2023
[Covid-19 vaccines, Di Bella therapy, alternative medicine and the "experts": who to believe?]Paolo Bruzzi
Recenti Progressi in Medicina|September 30, 2015
[Health registries: methodological issues]Paolo Bruzzi
Epidemiologia E Prevenzione|August 2, 2018
[Adaptive studies to assess drug effectiveness]Paolo Bruzzi, Giuseppe Traversa
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 22, 2016
Estimating a treatment effect: Choosing between relative and absolute measuresMaria Pia Sormani, Paolo Bruzzi
Nature Reviews. Neurology|December 24, 2014
Can we measure long-term treatment effects in multiple sclerosis?Maria Pia Sormani, Paolo Bruzzi
The Lancet. Neurology|June 8, 2013
MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trialsMaria Pia Sormani, Paolo Bruzzi
BMJ Open|January 14, 2021
Key drivers of innovativeness appraisal for medicines: the Italian experience after the adoption of the new ranking systemCarlotta Galeone, Paolo Bruzzi, Claudio Jommi
European Journal of Cancer (Oxford, England : 1990)|July 29, 2017
The urgent need to improve the tools to assess clinical benefit and value of cancer treatmentAlberto Sobrero, Alberto Puccini, Giacomo Bregni, et al.
Mutation Research|July 18, 2006
Molecular epidemiology: new rules for new tools?Domenico Franco Merlo, Maria Pia Sormani, Paolo Bruzzi
Pageof 16

Showing results (1-10 of 155) with videos related to

Sort By:
Pageof 16
Annals of the New York Academy of Sciences|July 4, 2002
Objective response to treatment as a potential surrogate marker of survival in breast cancerPaolo Bruzzi
Recenti Progressi in Medicina|July 1, 2023
[Covid-19 vaccines, Di Bella therapy, alternative medicine and the "experts": who to believe?]Paolo Bruzzi
Recenti Progressi in Medicina|September 30, 2015
[Health registries: methodological issues]Paolo Bruzzi
Epidemiologia E Prevenzione|August 2, 2018
[Adaptive studies to assess drug effectiveness]Paolo Bruzzi, Giuseppe Traversa
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 22, 2016
Estimating a treatment effect: Choosing between relative and absolute measuresMaria Pia Sormani, Paolo Bruzzi
Nature Reviews. Neurology|December 24, 2014
Can we measure long-term treatment effects in multiple sclerosis?Maria Pia Sormani, Paolo Bruzzi
The Lancet. Neurology|June 8, 2013
MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trialsMaria Pia Sormani, Paolo Bruzzi
BMJ Open|January 14, 2021
Key drivers of innovativeness appraisal for medicines: the Italian experience after the adoption of the new ranking systemCarlotta Galeone, Paolo Bruzzi, Claudio Jommi
European Journal of Cancer (Oxford, England : 1990)|July 29, 2017
The urgent need to improve the tools to assess clinical benefit and value of cancer treatmentAlberto Sobrero, Alberto Puccini, Giacomo Bregni, et al.
Mutation Research|July 18, 2006
Molecular epidemiology: new rules for new tools?Domenico Franco Merlo, Maria Pia Sormani, Paolo Bruzzi
Pageof 16